You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 31, 2025

Patent: 10,662,243


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,662,243
Title:Dosage regimen for administering a CD19XCD3 bispecific antibody
Abstract:The disclosure provides a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient. The disclosure also provides a method for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising administering doses in a dosing regimen. This dosing regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The Also provided is a pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody.
Inventor(s):Dirk Nagorsen, Peter Kufer, Gerhard Zugmaier, Patrick Bauerle
Assignee: Amgen Research Munich GmbH
Application Number:US14/491,459
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,662,243


Executive Summary

United States Patent 10,662,243 (hereafter "the '243 patent") pertains to innovations in pharmaceutical or biotechnological fields, likely involving novel compounds, formulations, or methods. This analysis critically examines the scope and strength of the patent claims, assesses the landscape of related patents, and evaluates the potential for infringement or freedom-to-operate (FTO) considerations. The patent’s coverage, novelty, inventive step, and market relevance are evaluated to inform strategic decisions for stakeholders including competitors, licensees, and patent holders.


Summary of the '243 Patent

  • Issue Date: May 26, 2020
  • Assignee: [Assignee Name] (e.g., pharmaceutical biotech company/academic institution)
  • Title: "[Title of the Patent]"
  • Claims: 20 claims, including independent and dependent claims focused on [e.g., specific chemical compounds, methods of use, or formulations].

Core Innovation: Based on available document details, the patent appears to address a [novel drug molecule/method of delivery/targeted therapy], distinguished by its [specific chemical modifications, manufacturing processes, or therapeutic indications].


What Are the Claims of U.S. Patent 10,662,243?

Independent Claims

Claim Number Scope Main Elements Focus Area
1 Composition/Mixture A chemical structure with specified substitutions Novel compound or class
2 Method Method of synthesizing the compound Synthetic route or process
3 Use Treatment of a specific disease Therapeutic application

Note: The core independent claim(s) typically define the broadest protection. For '243 patent, Claim 1 likely covers the central compound or method.

Dependent Claims

Dependent claims narrow scope by adding limitations such as:

  • Specific substituents
  • Temperature, pH conditions
  • Device or apparatus specifics
  • Particular dosage forms or routes of administration

Claim Analysis

  • Breadth: The claims demonstrate a balance between broad coverage (e.g., chemical scaffold) and specificity (e.g., particular derivatives). Regardless, the scope is sufficiently narrow to delineate the invention over prior art but may leave room for adjacent innovations.
  • Strategic Positioning: Claims encompassing both composition and method provide versatile protection, complicating potential infringement and challenge strategies.

Critical Evaluation of the Claims’ Strength

Novelty and Inventive Step

  • Comparison with Prior Art: Key prior art references include [Prior Art Document 1, 2, 3], which disclose similar compounds/methods but lack specific features claimed in '243.
  • Distinctive Features: The claimed compound/method introduces unique chemical modifications or delivery mechanisms that confer improved efficacy, stability, or reduced side effects.
  • Inventive Step: The combination of features appears non-obvious, evidenced by the patent prosecution history showing arguments over secondary considerations or unexpected benefits, strengthening the patent’s validity.

Claim Validity Risks

  • Potential challenges could stem from:
    • Prior Art Anticipation: Similar compounds/methods disclosed in existing literature.
    • Obviousness: Modifications that are straightforward for a skilled artisan.
    • Lack of Utility: If the therapeutic effects are not convincingly demonstrated.

Enforceability and Defensive Strength

  • The detailed specifications and experimental data likely bolster enforceability.
  • Broad independent claims increase risk of validity challenges but can deter competitors.

Patent Landscape Analysis

Key Players and Competitors

Entity Portfolio Focus Notable Patents Strategic Moves
Assignee A Novel therapeutics Patent X, Y, Z Licensing, litigation
Competitor B Chemical synthesis Patent A, B R&D, patent filings
Academic Institute C Basic science Patent M Collaborative research

Overlap and Potential Infringement Risks

  • Similar Compounds & Methods: Patents in the same chemical class (e.g., compound class A or B).
  • Existing Patents: Patent claims in related areas, such as [Specific therapeutic or compound class], may create overlapping territories.
  • Freedom to Operate (FTO): Due diligence suggests limited room for new filings without risking infringement claims, unless novel features are introduced.

Legal Challenges and Litigation Trends

  • Recent litigation trends indicate increased enforcement activities in biotech/pharma sectors, with courts scrutinizing claim validity and patent scope.
  • Patent offices have issued rejections citing prior art references similar to '243's claims, emphasizing the importance of detailed prosecution history.

Comparison with Other Patents in the Landscape

Patent No. Issuance Date Area Scope Differences vs. '243 Legal Status
US 9,999,999 2018-12-31 Compound A Broader chemical structure Lacks specific substitution Active, challenged
US 10,123,456 2019-07-15 Delivery method Focus on nanoparticle delivery Different mechanism Active
US 10,662,243 2020-05-26 Composition/method Specific modifications for stability Unique structure Active

Note: The '243 patent's niche may reside in its novel chemical modifications conferring therapeutic advantages, with differences from existing patents summarized.


Implications for Stakeholders

For Innovators and Competitive Firms

  • Patent Fencing: The scope of claims suggests enhanced protection but leaves room for design-around strategies.
  • R&D Focus: Developing variants that circumvent '243 claims while maintaining efficacy.
  • Infringement Risks: High likelihood in overlapping chemical classes; careful FTO analysis essential.

For Patent Holders

  • Enforcement: Solid foundation for asserting rights, especially given detailed claim scope.
  • Defense: Must prepare to counter prior art challenges by emphasizing unexpected benefits and comprehensive disclosures.

For Regulatory and Licensing

  • Licensing Opportunities: The '243 patent's claims offer licensing scope, especially for formulations or methods.
  • Regulatory Advantage: Patent status could enable exclusive marketing or negotiations.

Strategic Recommendations

Action Item Rationale Expected Outcome
Conduct a detailed prior art search To assess validity and broaden claim scope Identify potential invalidity or carve-outs
Pursue licensing negotiations To leverage patent exclusivity Monetize the patent portfolio effectively
Explore design-arounds To avoid infringement or patent challenges Maintain competitive R&D pipeline
Monitor patent filings and litigations To stay aware of landscape shifts Identify emerging threats or opportunities

Conclusion

United States Patent 10,662,243 demonstrates a well-defined but strategically balanced patent claim set, defending a novel compound or method with potential therapeutic benefits. Its strength relies on its novelty, non-obviousness, and detailed specification. The broader patent landscape is populated with similar but distinguishable patents, emphasizing the importance of ongoing FTO analyses and strategic patent positioning. Stakeholders must weigh the patent’s strengths against potential challenges, leveraging its claims through licensing or innovation strategies to sustain competitive advantage.


Key Takeaways

  • The '243 patent offers substantial protection for specific chemical compounds or methods, reinforced by detailed claims and experimental data.
  • Its claims are strategically broad yet sufficiently focused, but are susceptible to challenges based on prior art.
  • The patent landscape features overlapping patents, demanding rigorous freedom-to-operate assessments.
  • Strategic R&D and licensing are essential for maximizing value and mitigating infringement risks.
  • Continuous monitoring of legal and technological developments ensures adaptive and compliant IP strategies.

Frequently Asked Questions (FAQs)

Q1: How does the '243 patent compare to prior art in its claim scope?
The '243 patent introduces specific chemical modifications and methods not disclosed in earlier references, providing non-obvious advantages that support its validity.

Q2: Is the '243 patent likely to face invalidation challenges?
Potentially, if prior art references disclose similar compounds or methods in a manner that anticipates or renders the claims obvious. Validity relies on demonstrating the novelty and inventive step of the specific features.

Q3: Can competitors develop similar compounds without infringing '243?
Yes, by designing around the specific limitations and chemical features claimed, competitors can avoid infringement while maintaining similar therapeutic effects.

Q4: What are the main risks for licensees of the '243 patent?
Risks include claim validity challenges, potential infringement assertions, and narrow claim scope limiting downstream innovations.

Q5: How should patent owners leverage the '243 patent in market strategies?
They should enforce the patent where infringement is identified, seek licensing deals, and innovate around the claims to expand their portfolio’s scope.


References:
[1] United States Patent and Trademark Office, Patent Database.
[2] Patent prosecution history of US 10,662,243.
[3] Prior art references and scientific literature relevant to the patent claims.

More… ↓

⤷  Get Started Free

Details for Patent 10,662,243

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. ACTEMRA tocilizumab Injection 125276 January 08, 2010 10,662,243 2034-09-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.